Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Iovance Biotherapeutics

DB:2LB
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2LB
DB
$4B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The last earnings update was 44 days ago. More info.


Add to Portfolio Compare Print
  • Iovance Biotherapeutics has significant price volatility in the past 3 months.
2LB Share Price and Events
7 Day Returns
6.1%
DB:2LB
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
165.1%
DB:2LB
-7.4%
DE Biotechs
-14.2%
DE Market
2LB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Iovance Biotherapeutics (2LB) 6.1% 6.4% 8.1% 165.1% 384.3% 141.2%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 2LB outperformed the Biotechs industry which returned -7.4% over the past year.
  • 2LB outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
2LB
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Iovance Biotherapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Iovance Biotherapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Iovance Biotherapeutics.

DB:2LB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:2LB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (0.29%))
1.034
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.03
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.034 * 5.44%)
5.23%

Discounted Cash Flow Calculation for DB:2LB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Iovance Biotherapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:2LB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.23%)
2020 -214.47 Analyst x3 -203.80
2021 -215.30 Analyst x3 -194.42
2022 -132.00 Analyst x2 -113.27
2023 61.53 Analyst x3 50.17
2024 230.63 Analyst x3 178.71
2025 384.99 Est @ 66.93% 283.47
2026 564.91 Est @ 46.73% 395.26
2027 749.04 Est @ 32.6% 498.02
2028 919.07 Est @ 22.7% 580.68
2029 1,064.04 Est @ 15.77% 638.83
Present value of next 10 years cash flows $2,113.00
DB:2LB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $1,064.04 × (1 + -0.39%) ÷ (5.23% – -0.39%)
$18,845.11
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $18,845.11 ÷ (1 + 5.23%)10
$11,314.35
DB:2LB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,113.00 + $11,314.35
$13,427.35
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $13,427.35 / 126.50
$106.15
DB:2LB Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:2LB represents 0.88909x of NasdaqGM:IOVA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88909x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 106.15 x 0.88909
€94.37
Value per share (EUR) From above. €94.37
Current discount Discount to share price of €27.46
= -1 x (€27.46 - €94.37) / €94.37
70.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Iovance Biotherapeutics is available for.
Intrinsic value
>50%
Share price is €27.46 vs Future cash flow value of €94.37
Current Discount Checks
For Iovance Biotherapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Iovance Biotherapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Iovance Biotherapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Iovance Biotherapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Iovance Biotherapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2LB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.59
NasdaqGM:IOVA Share Price ** NasdaqGM (2020-04-08) in USD $30.88
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Iovance Biotherapeutics.

DB:2LB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:IOVA Share Price ÷ EPS (both in USD)

= 30.88 ÷ -1.59

-19.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Iovance Biotherapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Iovance Biotherapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Iovance Biotherapeutics's expected growth come at a high price?
Raw Data
DB:2LB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -19.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
37.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Iovance Biotherapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Iovance Biotherapeutics's assets?
Raw Data
DB:2LB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.37
NasdaqGM:IOVA Share Price * NasdaqGM (2020-04-08) in USD $30.88
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:2LB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:IOVA Share Price ÷ Book Value per Share (both in USD)

= 30.88 ÷ 2.37

13.06x

* Primary Listing of Iovance Biotherapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Iovance Biotherapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Iovance Biotherapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Iovance Biotherapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Iovance Biotherapeutics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Iovance Biotherapeutics expected to grow at an attractive rate?
  • Iovance Biotherapeutics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Iovance Biotherapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Iovance Biotherapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:2LB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2LB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 37.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2LB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2LB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,047 156 132 6
2023-12-31 625 -21 -13 7
2022-12-31 265 -120 -191 7
2021-12-31 58 -228 -302 8
2020-12-31 0 -226 -274 9
2020-04-09
DB:2LB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -159 -198
2019-09-30 -137 -167
2019-06-30 -122 -151
2019-03-31 -112 -134
2018-12-31 -101 -124
2018-09-30 -91 -117
2018-06-30 -84 -105
2018-03-31 -78 -98
2017-12-31 -79 -92
2017-09-30 -70 -82
2017-06-30 -61 -128
2017-03-31 -47 -116

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Iovance Biotherapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Iovance Biotherapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2LB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Iovance Biotherapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2LB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.89 2.29 -1.51 6.00
2023-12-31 -0.11 1.95 -1.88 7.00
2022-12-31 -1.61 -0.45 -2.96 7.00
2021-12-31 -2.17 -1.69 -2.91 10.00
2020-12-31 -2.09 -1.71 -2.53 10.00
2020-04-09
DB:2LB Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.59
2019-09-30 -1.36
2019-06-30 -1.31
2019-03-31 -1.25
2018-12-31 -1.27
2018-09-30 -1.36
2018-06-30 -1.35
2018-03-31 -1.38
2017-12-31 -1.41
2017-09-30 -1.31
2017-06-30 -2.08
2017-03-31 -1.98

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Iovance Biotherapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Iovance Biotherapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Iovance Biotherapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Iovance Biotherapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Iovance Biotherapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Iovance Biotherapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Iovance Biotherapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Iovance Biotherapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Iovance Biotherapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Iovance Biotherapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2LB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -197.56 40.85 166.02
2019-09-30 -166.56 37.50 139.20
2019-06-30 -150.91 34.59 125.57
2019-03-31 -134.02 30.55 110.82
2018-12-31 -123.58 28.43 99.83
2018-09-30 -116.86 26.28 93.11
2018-06-30 -105.18 24.83 81.84
2018-03-31 -97.90 22.94 75.93
2017-12-31 -92.06 21.26 71.62
2017-09-30 -81.90 12.57 60.66
2017-06-30 -127.96 17.34 52.53
2017-03-31 -116.15 19.67 38.34
2016-12-31 -102.35 17.20 26.94
2016-09-30 -95.02 24.94 21.26
2016-06-30 -34.44 17.58 17.28
2016-03-31 -29.25 12.31 17.26
2015-12-31 -27.66 12.39 15.47
2015-09-30 -24.17 10.01 14.24
2015-06-30 -19.33 9.93 9.47
2015-03-31 -15.07 9.14 5.94
2014-12-31 -12.04 8.19 3.85
2014-09-30 -27.13 7.14 1.58
2014-06-30 -33.74 6.60 2.02
2014-03-31 -35.06 6.18 1.36
2013-12-31 -33.84 3.83 2.15
2013-09-30 -10.42 5.15 1.02
2013-06-30 -1.68 4.06 1.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Iovance Biotherapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Iovance Biotherapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Iovance Biotherapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Iovance Biotherapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Iovance Biotherapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Iovance Biotherapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Iovance Biotherapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Iovance Biotherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Iovance Biotherapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Iovance Biotherapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Iovance Biotherapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Iovance Biotherapeutics Company Filings, last reported 3 months ago.

DB:2LB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 298.97 0.00 307.08
2019-09-30 355.06 0.00 361.87
2019-06-30 397.42 0.00 404.15
2019-03-31 434.93 0.00 440.02
2018-12-31 466.19 0.00 468.52
2018-09-30 254.16 0.00 260.00
2018-06-30 270.57 0.00 276.10
2018-03-31 292.56 0.00 297.08
2017-12-31 145.48 0.00 145.37
2017-09-30 165.44 0.00 163.38
2017-06-30 129.15 0.00 129.02
2017-03-31 149.89 0.00 147.20
2016-12-31 166.92 0.00 166.47
2016-09-30 179.13 0.00 179.28
2016-06-30 188.94 0.00 191.57
2016-03-31 98.94 0.00 99.17
2015-12-31 104.02 0.00 103.70
2015-09-30 109.37 0.00 110.15
2015-06-30 112.87 0.00 112.34
2015-03-31 111.63 0.00 111.28
2014-12-31 44.85 0.00 44.91
2014-09-30 16.16 0.00 17.19
2014-06-30 17.38 0.00 18.45
2014-03-31 16.81 0.00 17.95
2013-12-31 17.60 0.00 19.67
2013-09-30 -3.34 0.00 0.13
2013-06-30 -2.77 0.00 0.57
  • Iovance Biotherapeutics has no debt.
  • Iovance Biotherapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Iovance Biotherapeutics has sufficient cash runway for 1.9 years based on current free cash flow.
  • Iovance Biotherapeutics has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 45.6% each year.
X
Financial health checks
We assess Iovance Biotherapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Iovance Biotherapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Iovance Biotherapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Iovance Biotherapeutics dividends.
If you bought €2,000 of Iovance Biotherapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Iovance Biotherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Iovance Biotherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2LB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2LB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Iovance Biotherapeutics has not reported any payouts.
  • Unable to verify if Iovance Biotherapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Iovance Biotherapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Iovance Biotherapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Iovance Biotherapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Iovance Biotherapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Iovance Biotherapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Iovance Biotherapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Maria Fardis
COMPENSATION $9,394,600
AGE 51
TENURE AS CEO 3.8 years
CEO Bio

Dr. Maria Fardis, PhD, MBA, has been the Chief Executive Officer and President of Iovance Biotherapeutics, Inc. since June 1, 2016. Previously, Dr. Fardis held a number of key scientific and management roles at Gilead Sciences. She has extensive experience in drug development and novel cancer treatments. Prior to joining Lion Biotechnologies, Dr. Fardis served as Chief Operating Officer at Acerta Pharma Since January 2015 until March 2016. At Acerta, she worked on the development of acalabrutinib (ACP-196) Dr. Fardis served as Chief of Oncology Operations and Alliances at Pharmacyclics Inc. since March 2013, where she oversaw development of ibrutinib (IMBRUVICA®), abexinostat (HDAC inhibitor), and FVIIa inhibitor programs. She was a key contributor in the creation of a broad clinical program for ibrutinib, as well as New Drug Application and Marketing Authorisation Application submissions. She served as Executive Vice President of Operations and Alliances at Pharmacyclics Inc. since September 2012. At Gilead, she was involved with multiple therapeutic areas including antivirals, oncology and cardiovascular therapeutics and worked on the development and life cycle management of ambrisentan (Letairis®). She has been a Director of Lion Biotechnologies, Inc. since June 7, 2016. Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley and her B.S. summa cum laude, in chemistry from the University of Illinois, Urbana-Champaign. Dr. Fardis holds an MBA, with highest honors, from Golden Gate University.

CEO Compensation
  • Maria's compensation has increased whilst company is loss making.
  • Maria's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Iovance Biotherapeutics management team in years:

3.3
Average Tenure
57
Average Age
  • The tenure for the Iovance Biotherapeutics management team is about average.
Management Team

Maria Fardis

TITLE
CEO, President & Director
COMPENSATION
$9M
AGE
51
TENURE
3.8 yrs

Tim Morris

TITLE
CFO, Principal Accounting Officer
COMPENSATION
$603K
AGE
57
TENURE
2.7 yrs

Frederick Vogt

TITLE
General Counsel
COMPENSATION
$503K
AGE
45
TENURE
2.8 yrs

Sara Pellegrino

TITLE
Vice President of Investor Relations & Public Relations

Howard Johnson

TITLE
Senior Vice President of Corporate Development
AGE
59
TENURE
4.7 yrs

Friedrich Graf Finckenstein

TITLE
Chief Medical Officer
TENURE
0.8 yrs

Kelly DiTrapani

TITLE
Vice President of Medical Affairs

Elma Hawkins

TITLE
Advisor to the Board
COMPENSATION
$3M
AGE
62
TENURE
3.8 yrs
Board of Directors Tenure

Average tenure and age of the Iovance Biotherapeutics board of directors in years:

3.8
Average Tenure
58.5
Average Age
  • The tenure for the Iovance Biotherapeutics board of directors is about average.
Board of Directors

Iain Dukes

TITLE
Chairman of the Board
COMPENSATION
$1M
AGE
61
TENURE
3.7 yrs

Maria Fardis

TITLE
CEO, President & Director
COMPENSATION
$9M
AGE
51
TENURE
3.8 yrs

Tony McPeak

TITLE
Independent Director
COMPENSATION
$561K
AGE
83
TENURE
8.8 yrs

Ryan Maynard

TITLE
Independent Director
COMPENSATION
$546K
AGE
50
TENURE
5.2 yrs

Michael Weiser

TITLE
Independent Director
COMPENSATION
$1M
AGE
56
TENURE
2.1 yrs

Cassian Yee

TITLE
Member of Scientific Advisory Board

Mario Sznol

TITLE
Member of Scientific Advisory Board
AGE
61

Jim Mulé

TITLE
Member of Scientific Advisory Board

Jeff Weber

TITLE
Member of Scientific Advisory Board

Patrick Hwu

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Iovance Biotherapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Iovance Biotherapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company’s lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

Details
Name: Iovance Biotherapeutics, Inc.
2LB
Exchange: DB
Founded: 2007
$3,592,208,424
126,498,470
Website: http://www.iovance.com
Address: Iovance Biotherapeutics, Inc.
999 Skyway Road,
Suite 150,
San Carlos,
California, 94070,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM IOVA Common Shares Nasdaq Global Market US USD 19. Jun 2008
DB 2LB Common Shares Deutsche Boerse AG DE EUR 19. Jun 2008
LSE 0JDK Common Shares London Stock Exchange GB USD 19. Jun 2008
Number of employees
Current staff
Staff numbers
148
Iovance Biotherapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 01:38
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/02/25
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.